Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE traded down $0.17 on Friday, hitting $55.60. 677,727 shares of the company's stock were exchanged, compared to its average volume of 832,705. Ultragenyx Pharmaceutical has a 12 month low of $45.20 and a 12 month high of $104.38. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -7.60 and a beta of 1.21. The business's 50 day simple moving average is $55.66 and its two-hundred day simple moving average is $63.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company had revenue of $89.34 million during the quarter, compared to analysts' expectations of $87.33 million. During the same quarter last year, the firm earned ($1.45) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 2.7% on a year-over-year basis. Equities analysts forecast that Ultragenyx Pharmaceutical will post -7.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the subject of several recent research reports. Citigroup reduced their target price on shares of Ultragenyx Pharmaceutical from $146.00 to $142.00 in a research note on Wednesday. Stifel Nicolaus reduced their target price on shares of Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an "overweight" rating for the company in a research note on Thursday, July 28th. The Goldman Sachs Group reduced their target price on shares of Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a "neutral" rating for the company in a research note on Tuesday, May 24th. Finally, Cowen reduced their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $99.00 in a research note on Friday, May 6th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $112.67.